| Document |
Document Title |
|
WO/2024/064701A2 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2024/061390A1 |
The invention provides compounds of general formula (I) wherein each of X is CH or N, wherein at most one X is N; Y is CH or N; R1 is selected from H, halogen; R2 is selected from H, C1-C4 alkyl, C1-C4 alkylamino, C3-C6 cykloalkylamino; ...
|
|
WO/2024/064825A1 |
Described herein is a method of treating a neurological or psychiatric condition comprising administering a methylenedioxy derived designer drug or a benzofuran derived designer drug, to a mammal in need thereof. Also described herein us...
|
|
WO/2024/063624A1 |
The present invention relates to: an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 or an antigen-binding fragment thereof; and a pharmaceutical composition for treating cancer, comprising same as...
|
|
WO/2024/064779A1 |
The present invention provides a compound of Formula I: wherein R is H or; R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or C...
|
|
WO/2024/064851A2 |
The disclosure relates to compositions and methods comprising recombinant AAV vectors comprising polynucleotide sequences encoding superoxide dismutase (SOD) proteins. Also included are methods of treating or preventing acute, progressiv...
|
|
WO/2023/055648A9 |
A solid dispersion matrix formulation, comprising CBD and a polymer selected from the group consisting of polyvinylpyrrolidone (PVP) and poly (vinylpyrrolidone-vinyl acetate) copolymer, and mixtures thereof, and wherein CBD is non-crysta...
|
|
WO/2024/064784A2 |
Provided herein are methods of treating a mitral valve disease in a subject. The methods involve administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTG...
|
|
WO/2024/063248A1 |
An electronic device according to an embodiment may comprise: a cartridge reception portion which receives a cartridge including an emulsion therein; a crushing circuit including a crushing element capable of crushing at least a part of ...
|
|
WO/2024/064151A1 |
The present disclosure provides methods of treating an individual for a muco-obstructive, the methods including: administering to the individual a b-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic ...
|
|
WO/2024/061187A1 |
Provided in the present disclosure are stilbene derivatives, a preparation method therefor and the use thereof. Specifically, provided in the present disclosure is the use of compounds represented by formula (I-1), and stereoisomers, pha...
|
|
WO/2024/064655A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including n...
|
|
WO/2024/063740A2 |
The invention relates to hydrazide and hydrazide-hydrazone derivative molecules with antitumoral effect, bearing 1,2,4-triazole rings, which are effective on the MCF-7 breast cancer cell line and on cyclooxygenase-1 (COX-1 ), especially ...
|
|
WO/2024/061158A1 |
The antibodies bind to SLIT2 and related substitution mutants, including their manufacture and use.
|
|
WO/2023/212033A9 |
This invention relates generally to injectable drug delivery systems and methods of preparing same, and in particular to drug delivery systems comprising biodegradable polymeric nanogel formulations that form a depot (gel) in the body on...
|
|
WO/2024/064002A1 |
OKI-179 alone or in combination with a MAPK pathway inhibitor is described for the treatment of a cancer resulting from one or more mutations in the MAPK pathway.
|
|
WO/2024/060838A1 |
Provided is a praziquantel pill suitable for distribution by unmanned aerial vehicles, comprising: praziquantel, and a bait layer and a waterproof layer that sequentially encapsulate praziquantel from inside to outside. The waterproof la...
|
|
WO/2024/064608A2 |
Provided herein are expression constructs, nucleic acid vectors, pharmaceutical compositions, and methods for improved expression of functional BEST1 in subjects having mutations in BEST1 and associated retinal dystrophies. Improved expr...
|
|
WO/2024/064336A1 |
A dressing including a top film, an adhesive layer positioned adjacent the top film closer to a user's skin when the bandage is in use, a hydrogel layer including a support layer, below the adhesive layer closer to the user's skin when t...
|
|
WO/2024/064102A1 |
Disclosed herein are compositions and methods for treating, improving or ameliorating a disease or condition associated with intestinal permeability, improving intestinal permeability, and improving gut barrier function in a subject. Som...
|
|
WO/2024/062421A1 |
The present invention discloses polymorphs of bexagliflozin or hydraates of bexagliflozin, as crystalline solids, processes for the preparation of the polymorphs/hydrates of bexagliflozin as crystalline solids, pharmaceutical composition...
|
|
WO/2024/064358A1 |
This disclosure features chemical entities (e.g., a compound of Formula (I), (I-a), (I-b), or (I-c), or a pharmaceutically acceptable salt thereof) that induce degradation of Stimulator of Interferon Genes (STING). Said chemical entities...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/064724A1 |
This invention relates to methods of treating cancer, enhancing an immune response and/or reducing and/or reversing immunosuppression to cancer in a subject having, suspected to have and/or at risk of cancer. The invention further relate...
|
|
WO/2024/061345A1 |
The present application belongs to the field of medicines, and provides an HPK1 inhibitor, a preparation method therefor, and use thereof. Particularly, disclosed are a compound of formula (I'), a preparation method therefor, a pharmaceu...
|
|
WO/2024/062235A1 |
The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives...
|
|
WO/2024/061367A1 |
Disclosed are a novel compound, a pharmaceutical composition thereof, and use thereof. The novel compound is represented by formula (I), wherein the details of the definition of each substituent group are shown in the specification. The ...
|
|
WO/2024/062077A1 |
A composition comprising a phlorotannin or a α-fucan, or a combination thereof, for use in priming the endocrine system and enhancing insulin sensitivity, and for use in treating or preventing a disease or condition of an animal caused ...
|
|
WO/2024/059946A1 |
Multivalent trident aptamers comprising the general formula [A-SA]2 or 3-L-[SB-B] in which a central branched linker molecule (L) possesses 2 or 3 variable arms ([A-SA]2 or 3), and a root ([SB-B]), connected by a central carbon atom, to ...
|
|
WO/2024/064690A1 |
Disclosed herein are polymorph forms of (S)-N-(2-amino-l-(3-chloro-5-fluorophenyl)ethyl)-l-(5- methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-lH
-imidazole-4-carboxamide, L- mandelic acid salt:
|
|
WO/2024/064897A1 |
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
|
|
WO/2024/061343A1 |
The present disclosure relates to a PKMYT1 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound or the pharmaceut...
|
|
WO/2024/061213A1 |
The present invention provides a carbonyl fused heterocyclic derivative used as a ubiquitin-specific protease inhibitor, and specifically relates to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptab...
|
|
WO/2024/059947A1 |
The present disclosure relates to molecular recognition elements (MREs) and, in particular, to aptamers for recognizing and binding to a microorganism, a virus, and/or a molecule present on a microorganism or virus, such as spike protein...
|
|
WO/2024/063285A1 |
The present invention relates to an industrially useful and pharmaceutically stable monohydrate of avibactam sodium and a preparation method therefor. The compound of the present invention can be used as a beta-lactamase inhibitor.
|
|
WO/2024/063576A1 |
The present invention relates to a novel quinazoline compound as a KRAS inhibitor and, more specifically, to a novel quinazoline compound useful as a KRAS protein inhibitor, an isomer, and a pharmaceutical composition for cancer treatmen...
|
|
WO/2024/064796A2 |
The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transfor...
|
|
WO/2024/064327A1 |
A nutritional composition for use in enhancing one or more features or functions of the blood-brain barrier, including promoting healing or improved function of the blood-brain barrier. In certain embodiments, a method comprises administ...
|
|
WO/2024/062090A1 |
A compound with the Formula (I): A-B-C wherein A is of the formula (Ia) where X1 is N B is of formula (B-1) or (B-2) and C is selected from the group consisting of optionally substituted C6-10 carboaryl, C5-6 heteroaryl and C5-10 heteroc...
|
|
WO/2024/060373A1 |
Provided are a (+)-flurbiprofen salt derivative, a compound represented by the following formula (I), a method for preparing same, a pharmaceutical composition thereof, and use thereof.
|
|
WO/2024/061203A1 |
Provided herein are a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib ...
|
|
WO/2024/006537A9 |
The disclosure relates to methods of using bile acid derivatives for the treatment and/or prevention of cognitive disorders, diseases, or conditions.
|
|
WO/2024/064316A1 |
Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
|
|
WO/2024/061251A1 |
Disclosed in the present invention is the novel use of 4-(trimethylammonio)pentanoate (4-TMAP). The present invention particularly relates to the use of 4-(trimethylammonio)pentanoate in preparation of drugs for treating depression. Also...
|
|
WO/2024/061267A1 |
A pharmaceutical composition, and a preparation method therefor and the use thereof. The pharmaceutical composition contains: (4aR,8R)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-
8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,...
|
|
WO/2024/061971A1 |
The invention provides different types of floating composition of diaminophenothiazine (DAPTZ) compounds such as methylene blue, which provide rapid-release in the stomach, or are gastro-retained. They further provide methods of making a...
|
|
WO/2024/064769A1 |
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides T cells which have been treated ex vivo with one or more oligonucleotide agents...
|
|
WO/2024/061271A1 |
Disclosed is a biotinylated heparin pentasaccharide capable of being neutralized, which has a structure as represented by formula (I). The anti-coagulation activity of the biotinylated heparin pentasaccharide capable of being neutralized...
|
|
WO/2024/063140A1 |
The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In formula (I), A1 is C(R5) or N, A2 is C(R6) or N, A3 is C(R7) or N, R5, R6, and R7 are each independently a hydrog...
|
|
WO/2024/064785A2 |
The present disclosure provides methods of treating familial partial lipodystrophy (FPL) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transformi...
|
